Weighing GLP-1 coverage
PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is uneven. What is needed is more data about whether these drugs can lower overall healthcare costs.
SMA Drugs Jockey for Position
Roche’s Evrysdi is the market leader among the drugs for spinal muscular atrophy. Biogen’s Spinraza has struggled, but company officials express confidence about future sales.
A Conversation With Laila Gharzai, M.D.
On financial toxicity, and when, how and by whom it should be discussed.
